Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +39.21%
#3 OriginTrail OriginTrail +21.06%
#4 ApeX ApeX +18.59%
#5 Zora Zora +17.74%
#6 Morpho Morpho +17.47%
#7 龙虾 (Lobster) 龙虾 (Lobster) +16.50%
#8 Non-Playable Coin Non-Playable Coin +16.01%
#9 Wrapped XPL Wrapped XPL +15.54%
#10 UnifAI Network UnifAI Network +15.45%
Coin of the day
Smilek to the Bank Smilek to the Bank
設定
言語
日本
通貨
USD
テーマ
Cyteir Therapeutics, Inc. Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYT
株式のランク #21570
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.
株価
$3.01
最終同期: 2024-04-12
時価総額
$104.64M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Cyteir Therapeutics, Inc. (CYT)

カテゴリー

Healthcare
Cyteir Therapeutics, Inc.（CYT）の収益
Aug 2026 時点の収益 TTM: 0
Cyteir Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cyteir Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH